326 related articles for article (PubMed ID: 31271281)
21. Design, synthesis and biological evaluation of novel hydroxamic acid based histone deacetylase 6 selective inhibitors bearing phenylpyrazol scaffold as surface recognition motif.
Yang J; Cheng G; Xu Q; Luan S; Wang S; Liu D; Zhao L
Bioorg Med Chem; 2018 May; 26(8):1418-1425. PubMed ID: 29500130
[TBL] [Abstract][Full Text] [Related]
22. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Liang T; Xue J; Yao Z; Ye Y; Yang X; Hou X; Fang H
Eur J Med Chem; 2021 Oct; 221():113526. PubMed ID: 33992929
[TBL] [Abstract][Full Text] [Related]
24. Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.
Bat-Erdene A; Nakamura S; Oda A; Iwasa M; Teramachi J; Ashtar M; Harada T; Miki H; Tenshin H; Hiasa M; Fujii S; Sogabe K; Oura M; Udaka K; Kagawa K; Yoshida S; Aihara KI; Kurahashi K; Endo I; Abe M
Br J Haematol; 2019 Jun; 185(5):969-974. PubMed ID: 30474853
[No Abstract] [Full Text] [Related]
25. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344.
Dawood M; Fleischer E; Klinger A; Bringmann G; Shan L; Efferth T
Pharmacol Res; 2020 Oct; 160():105076. PubMed ID: 32659428
[TBL] [Abstract][Full Text] [Related]
27. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
Wang XX; Xie F; Jia CC; Yan N; Zeng YL; Wu JD; Liu ZP
Eur J Med Chem; 2021 Dec; 225():113821. PubMed ID: 34517222
[TBL] [Abstract][Full Text] [Related]
29. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
[TBL] [Abstract][Full Text] [Related]
30. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Tavares MT; Kozikowski AP; Shen S
Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
[TBL] [Abstract][Full Text] [Related]
31. Development and Validation of High-Content Analysis for Screening HDAC6-Selective Inhibitors.
Nong Y; Hou Y; Pu Y; Li S; Lan Y
SLAS Discov; 2021 Jun; 26(5):628-641. PubMed ID: 33783263
[TBL] [Abstract][Full Text] [Related]
32. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
[TBL] [Abstract][Full Text] [Related]
34. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of 1H-benzo[d]imidazole selective HDAC6 inhibitors with potential therapy for multiple myeloma.
Liu L; Zhang L; Chen X; Yang K; Cui H; Qian R; Zhao S; Wang L; Su X; Zhao M; Wang M; Hu Z; Lu T; Zhu Y; Zhou QQ; Yao Y
Eur J Med Chem; 2023 Dec; 261():115833. PubMed ID: 37797564
[TBL] [Abstract][Full Text] [Related]
36. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models.
Depetter Y; Geurs S; De Vreese R; Goethals S; Vandoorn E; Laevens A; Steenbrugge J; Meyer E; de Tullio P; Bracke M; D'hooghe M; De Wever O
Int J Cancer; 2019 Aug; 145(3):735-747. PubMed ID: 30694564
[TBL] [Abstract][Full Text] [Related]
37. A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders.
Yang K; Zhao Y; Nie X; Wu H; Wang B; Almodovar-Rivera CM; Xie H; Tang W
Cell Chem Biol; 2020 Jul; 27(7):866-876.e8. PubMed ID: 32413286
[TBL] [Abstract][Full Text] [Related]
38. Odd-chain fatty acids as novel histone deacetylase 6 (HDAC6) inhibitors.
Ediriweera MK; To NB; Lim Y; Cho SK
Biochimie; 2021 Jul; 186():147-156. PubMed ID: 33965456
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Novel Histone Deacetylase 6 (HDAC6) Inhibitors with Enhanced Antitumor Immunity of Anti-PD-L1 Immunotherapy in Melanoma.
Peng X; Li L; Chen J; Ren Y; Liu J; Yu Z; Cao H; Chen J
J Med Chem; 2022 Feb; 65(3):2434-2457. PubMed ID: 35043615
[TBL] [Abstract][Full Text] [Related]
40. The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma.
Sun X; Xie Y; Sun X; Yao Y; Li H; Li Z; Yao R; Xu K
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30782785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]